Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.
Not a healthcare professional? Go to the patient or caregiver website.

XYNTHA® Solofuse Lyophilized Powder for Solution in Prefilled Dual-chamber Syringe Patient Counseling Information (antihemophilic factor [Recombinant])

17 PATIENT COUNSELING INFORMATION

Advise patients to:

  • read the FDA-approved patient labeling (Patient Information and Instructions for Use).
  • report any adverse reactions or problems that concern them when taking XYNTHA to their healthcare provider.
  • discontinue use of the product, call their healthcare provider, and go to the emergency department if any allergic-type hypersensitivity reactions occur. Inform patients of the early signs of hypersensitivity reactions (including hives [rash with itching], generalized urticaria, tightness of the chest, wheezing, hypotension) and anaphylaxis.
  • contact their healthcare provider if they experience a lack of a clinical response to factor VIII replacement therapy, as this may be a manifestation of an inhibitor.
  • notify their healthcare provider if they become pregnant or intend to become pregnant during therapy, or if they are breastfeeding.
  • Local irritation may occur when infusing XYNTHA SOLOFUSE.
Did you find an answer to your question? Yes No
Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event